EUCTR2020-005226-28-IT进行中（未招募）1 期
A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19 - na
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 40,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Increased risk of SARS-CoV-2 infection, Defined as adults whose
- •locations or circumstances put them at appreciable risk of exposure to
- •SARS-CoV-2 and COVID-19, based on available risk assessment
- •contemporaneous to enrollment (believed to be at risk/exposure)
- •- Medically stable such that, according to the judgment of the
- •investigator, hospitalization within the study period is not anticipated
- •and the participant appears likely to be able to remain on study through
- •the end of protocol-specified follow-up. A stable medical condition is
- •defined as disease not requiring significant change in therapy or
- •hospitalization for worsening disease during the 3 months prior to
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 30000
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10000
排除标准
- •Any confirmed or suspected immunosuppressive or immunodeficient
- •state, including asplenia
- •- Any other significant disease, disorder, or finding that may significantly
- •increase the risk to the participant because of participation in the study,
- •affect the ability of the participant to participate in the study, or impair
- •interpretation of the study data
- •- Receipt of, or planned receipt of investigational products indicated for
- •the treatment or prevention of SARS-CoV-2 or COVID-19 Note: For
- •participants who become hospitalized with COVID-19, receipt of licensed
- •treatment options and/orparticipation in investigational treatment
- •studies is permitted
研究者
相似试验
未知
3 期
A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate the Efficacy at 24 Weeks and to Assess the Long Term Efficacy, Safety, Tolerability and Usability up to 5 Years in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Anti-TNFalpha AgentsRheumatoid ArthritisJPRN-jRCT2080222045ovartis Pharma K.K.234
已完成
不适用
Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM) STORM-D015 Liver, gallbladder and bile ductsLiver, gallbladder and bile ductsD015PER-145-08BAYER S.A.,
进行中（未招募）
1 期
Phase III, double-blinded study using AZD7442 or Placebo for the prevention of COVID-19 disease in adults who have not been exposed to COVID-19 infectioCOVID-19MedDRA version: 23.0Level: PTClassification code 10051905Term: Coronavirus infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2020-004356-16-FRAstraZeneca AB5,000
进行中（未招募）
1 期
Phase 3, Double-blind, Placebo-controlled Study of AZD7442 for Treatment of COVID-19 in Outpatient AdultsCOVID-19 (Coronavirus Disease 2019)MedDRA version: 23.0Level: PTClassification code 10051905Term: Coronavirus infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2020-005315-44-HUAstraZeneca AB1,700
进行中（未招募）
1 期
Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in AdultsSARS-COV-2 infection (COVID-19)MedDRA version: 23.0Level: PTClassification code 10051905Term: Coronavirus infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2020-005226-28-FRAstraZeneca AB40,000